Market Research Report
Soft Tissue Sarcoma (STS) Market Insights, Epidemiology, and Market Forecast - 2028
|Published by||DelveInsight Business Research LLP||Product code||534851|
|Published||Content info||440 Pages
Delivery time: 1-2 business days
|Soft Tissue Sarcoma (STS) Market Insights, Epidemiology, and Market Forecast - 2028|
|Published: December 1, 2019||Content info: 440 Pages||
DelveInsight's 'Soft Tissue Sarcoma (STS) - Market Insights, Epidemiology, and Market Forecast-2028' report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of STS in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
According to the World Health Organization (WHO), there are more than 50 histologic subtypes of STSs. The signs and symptoms of STSs vary greatly from patients to patients based on the type of STS. However, it is not associated with any noticeable symptoms early in the course of the disease but the affected individuals may notice slow-growing, painless mass in the affected area.
According to DelveInsight's, STS have various subtypes. It was observed that in the United States and European countries, liposarcoma and leiomyosarcoma were the most incident subtypes of STS, which contributed to majority of the cases. Whereas in Japan, subtypes, fibroblastic sarcomas and liposarcoma were more common.
Study Period: 2017-2028
Soft-tissue sarcoma (STS) are rare neoplasms that can develop in supporting or connective tissue, such as the muscle, nerves, tendons, blood vessels and fatty and fibrous tissues. They commonly affect the arms, legs, and trunk. They also appear in the stomach and intestines (GIST) as well as behind the abdomen (retroperitoneal sarcomas) and the female reproductive system (gynecological sarcomas). STSs may be classified according to the involved cell-type, the specific nature of the malignancy, and the disease's clinical course.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Incident Cases of Soft Tissue Sarcoma (STS) in the 7MM, Type-specific Incidence Cases of Soft Tissue Sarcoma (STS) in the 7MM, Total Incident Cases of Gastrointestinal Stromal Tumor (GIST) in the United States, Total Incident Cases of STS including GIST in the United States and Incidence of STS by Extremities (%) in the 7MM scenario of STS in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.
According to DelveInsight's, the total incident population of Soft Tissue Sarcoma (STS) in seven major markets was 40,155 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2028).
Among all the seven major markets, United States accounts for highest number of cases of STS. In 2017, there were 12,390 incident cases of STS-which did not included GIST cases-in the United States. The total incident cases of GIST which were observed in the United States in 2017 accounted for 5,090. This lead to the total incident population of STS to 17,480 in 2017.
STS are a heterogeneous group of malignancies and relatively rare that are characterized by mesodermal differentiation. It is primarily encountered in adults but can affect patients of any age. There are many histologic subtypes, and the malignancy can be low or high grade. Soft tissue sarcoma treatments may include surgery, chemotherapy, radiation therapy, or a combination of these therapies.
The emerging therapies are classified into four categories based on their line of therapy. The upcoming first-line therapies that are going to be launched in the forecasted period includes, AL3818 (anlotinib), Fibromun. The second-line emerging therapies includes, Vigil in combination with irinotecan and temozolomide, AL3818, GSK 3377794, Ripretinib (DCC-2618), Tazemetostat, Abemaciclib, Pembrolizumab, Crizotinib, ABI-009, and SRA737. The third-line emerging therapies includes, Avapritinib, Cabozantinib, and Selinexor. The fourth-line emerging therapies includes Avapritinib, TAS-116, Crenolanib, and Ripretinib.
According to DelveInsight, the total market size of Soft Tissue Sarcoma (STS) excluding GIST in seven major markets was USD 246.7 million in 2017. The market size of STS is expected to increase at a significant CAGR during the study period (2017-2028).
Among all the seven major markets, United States accounts for highest market size of STS. In 2017, the market size of STS (excluding GIST) was found to be USD 142.18 million.
The current market size of STS is mainly attributed by Votrient, Yondelis, Halaven and various anthracycline and non-anthracycline regimens. The market size of GIST in the United States was found to be USD 119.7 million in 2017 and expected to increase during the forecast period (2019-2028), due to potential therapies Vitrakvi, Rozlytrek, Avapritinib, Ripretinib and others. Among EU5, Germany had the highest market size in 2017 with revenue USD 22.06 million followed by Italy with revenue USD 18.84 million. The market size of STS (excluding GIST) in Japan was found to be USD 17.60 million in 2017.